Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GSK837149A
Cat. No.:
OB0425LY-056
Appearance:
Solid
Purity:
≥99.0%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
GSK837149A is an active and selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain.
Synonyms:
13616-29-0; 4,4'-(Carbonylbis(azanediyl))bis(N-(4-methylpyrimidin-2-yl)benzenesulfonamidE); GSK837149; GSK-837149A; N, N'-Di[4-(4-Methyl-pyrimidin-2-ylsulfamoyl)phenyl]-urea
CAS No.:
13616-29-0
Compound CID:
57519517
Formula:
C23H22N8O5S2
Formula Weight:
554.6
Specification
Target:
Fatty acid synthase (FASN)
Pathway:
Metabolic enzyme/Protease
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
GSK837149A can be used for the research of obesity and breast cancer.
